Efficacy and Safety of Thulium Laser Vaporization of the Prostate: A Transurethral Procedure for Benign Prostatic Hyperplasia

IF 1.5 4区医学 Q3 UROLOGY & NEPHROLOGY

LUTS: Lower Urinary Tract Symptoms Pub Date : 2025-04-14 DOI:10.1111/luts.70012

Daisuke Gotoh, Kazumasa Torimoto, Akira Tachibana, Nobutaka Nishimura, Mitsuru Tomizawa, Kenta Onishi, Yosuke Morizawa, Shunta Hori, Yasushi Nakai, Makito Miyake, Kiyohide Fujimoto

{"title":"Efficacy and Safety of Thulium Laser Vaporization of the Prostate: A Transurethral Procedure for Benign Prostatic Hyperplasia","authors":"Daisuke Gotoh, Kazumasa Torimoto, Akira Tachibana, Nobutaka Nishimura, Mitsuru Tomizawa, Kenta Onishi, Yosuke Morizawa, Shunta Hori, Yasushi Nakai, Makito Miyake, Kiyohide Fujimoto","doi":"10.1111/luts.70012","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objectives</h3>\n \n <p>To explore the efficacy and safety of thulium laser vaporization of the prostate (ThuVAP) for benign prostatic hyperplasia (BPH) at Nara Medical University from 2022 to 2024.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Patients with BPH who underwent ThuVAP at the Department of Urology, Nara Medical University, between January 01, 2022 and April 30, 2024, were enrolled. Patient background, presurgical pressure flow study results, treatment efficacy, and safety were retrospectively evaluated.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The study included 32 patients; the median age was 74.5 years at surgery. The total International Prostate Symptom Score and quality of life were significantly lower at 4 weeks after surgery than at baseline. They continued to decrease at 12 and 24 weeks. The maximum flow rate was significantly higher at 4 weeks after surgery than at baseline; it continued to increase for 12 and 24 weeks. The postvoid residual (PVR) was significantly lower at 4 weeks after surgery than at baseline and continued to decrease at 12 and 24 weeks.</p>\n \n <p>Intravesical prostatic protrusion and prostate volume were positively correlated with the surgery and laser usage times. Two patients experienced temporary urinary retention, and two underwent transurethral electrocoagulation for postoperative bleeding.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Our data confirm ThuVAP as an effective and safe treatment for BPH.</p>\n </section>\n </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"17 3","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"LUTS: Lower Urinary Tract Symptoms","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/luts.70012","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

To explore the efficacy and safety of thulium laser vaporization of the prostate (ThuVAP) for benign prostatic hyperplasia (BPH) at Nara Medical University from 2022 to 2024.

Methods

Patients with BPH who underwent ThuVAP at the Department of Urology, Nara Medical University, between January 01, 2022 and April 30, 2024, were enrolled. Patient background, presurgical pressure flow study results, treatment efficacy, and safety were retrospectively evaluated.

Results

The study included 32 patients; the median age was 74.5 years at surgery. The total International Prostate Symptom Score and quality of life were significantly lower at 4 weeks after surgery than at baseline. They continued to decrease at 12 and 24 weeks. The maximum flow rate was significantly higher at 4 weeks after surgery than at baseline; it continued to increase for 12 and 24 weeks. The postvoid residual (PVR) was significantly lower at 4 weeks after surgery than at baseline and continued to decrease at 12 and 24 weeks.

Intravesical prostatic protrusion and prostate volume were positively correlated with the surgery and laser usage times. Two patients experienced temporary urinary retention, and two underwent transurethral electrocoagulation for postoperative bleeding.

Conclusions

Our data confirm ThuVAP as an effective and safe treatment for BPH.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

LUTS: Lower Urinary Tract Symptoms UROLOGY & NEPHROLOGY-

CiteScore

3.00

自引率

7.70%

发文量

审稿时长

>12 weeks

期刊介绍： LUTS is designed for the timely communication of peer-reviewed studies which provides new clinical and basic science information to physicians and researchers in the field of neurourology, urodynamics and urogynecology. Contributions are reviewed and selected by a group of distinguished referees from around the world, some of whom constitute the journal''s Editorial Board. The journal covers both basic and clinical research on lower urinary tract dysfunctions (LUTD), such as overactive bladder (OAB), detrusor underactivity, benign prostatic hyperplasia (BPH), bladder outlet obstruction (BOO), urinary incontinence, pelvic organ prolapse (POP), painful bladder syndrome (PBS), as well as on other relevant conditions. Case reports are published only if new findings are provided. LUTS is an official journal of the Japanese Continence Society, the Korean Continence Society, and the Taiwanese Continence Society. Submission of papers from all countries are welcome. LUTS has been accepted into Science Citation Index Expanded (SCIE) with a 2011 Impact Factor.